Marks Group Wealth Management Inc Reduces Position in IDEXX Laboratories, Inc. $IDXX

Marks Group Wealth Management Inc lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.1% in the 4th quarter, Holdings Channel reports. The fund owned 7,972 shares of the company’s stock after selling 2,129 shares during the quarter. Marks Group Wealth Management Inc’s holdings in IDEXX Laboratories were worth $5,393,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of IDXX. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories during the 4th quarter valued at about $3,666,459,000. Northwestern Mutual Wealth Management Co. grew its stake in IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after acquiring an additional 1,442,174 shares in the last quarter. Norges Bank purchased a new stake in IDEXX Laboratories during the 4th quarter valued at about $332,265,000. JPMorgan Chase & Co. grew its stake in IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after acquiring an additional 326,348 shares in the last quarter. Finally, Zurich Insurance Group Ltd FI purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at about $143,730,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research reports. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. UBS Group dropped their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Piper Sandler decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $561.17 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market capitalization of $44.27 billion, a price-to-earnings ratio of 41.32, a PEG ratio of 3.08 and a beta of 1.55. The company’s 50-day moving average is $562.81 and its two-hundred day moving average is $631.11. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.